Literature DB >> 21400563

Alternative splicing dysregulation secondary to skeletal muscle regeneration.

James P Orengo1, Amanda J Ward, Thomas A Cooper.   

Abstract

OBJECTIVE: Dysregulation of alternative splicing has become a molecular hallmark of myotonic dystrophy type 1 (DM1), in which neonatal splice variants are expressed in adult skeletal muscle. Splicing dysregulation is induced by RNA containing expanded CUG repeats expressed from the expanded mutant allele by sequestration of muscleblindlike 1 (MBNL1) protein within nuclear RNA foci and increased CUGBP, ELAV-like family member 1 (CELF1) protein levels. Dysregulated splicing has also been identified in other neuromuscular disorders, suggesting either that diseases with different molecular causes share a common pathogenic mechanism or that dysregulated splicing can also be a common secondary consequence of muscle degeneration and regeneration.
METHODS: In this study, we examined regulation of alternative splicing in 4 different mouse models of muscular dystrophy, including DM1, limb-girdle muscular dystrophy, congenital merosin-deficient muscular dystrophy, and Duchenne muscular dystrophy, and 2 myotoxin (cardiotoxin and notexin) muscle injury models.
RESULTS: We show that DM1-like alternative splicing dysregulation and altered expression of MBNL1 and CELF1 occur in non-DM1 mouse models of muscular dystrophy and muscle injury, most likely due to recapitulation of neonatal splicing patterns in regenerating fibers. In contrast, CELF1 was elevated in nuclei of mature myofibers of the DM1 model, consistent with a primary effect of pathogenic RNA expression.
INTERPRETATION: Splicing dysregulation in DM1 is a primary effect of RNA containing expanded CUG repeats. However, we conclude that splicing changes can also be observed secondary to muscle regeneration, and this possibility must be taken into account when evaluating cause-effect relationships between dysregulated splicing and disease processes.
Copyright © 2010 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21400563      PMCID: PMC3082633          DOI: 10.1002/ana.22278

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  41 in total

1.  The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing.

Authors:  A N Ladd; N Charlet; T A Cooper
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Defective satellite cells in congenital myotonic dystrophy.

Authors:  D Furling; L Coiffier; V Mouly; J P Barbet; J L St Guily; K Taneja; G Gourdon; C Junien; G S Butler-Browne
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

3.  Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.

Authors:  A Mankodi; C R Urbinati; Q P Yuan; R T Moxley; V Sansone; M Krym; D Henderson; M Schalling; M S Swanson; C A Thornton
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

4.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

5.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

6.  Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E.

Authors:  M Durbeej; R D Cohn; R F Hrstka; S A Moore; V Allamand; B L Davidson; R A Williamson; K P Campbell
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

7.  CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.

Authors:  Amanda J Ward; Mendell Rimer; James M Killian; James J Dowling; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2010-07-05       Impact factor: 6.150

8.  A muscleblind knockout model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Karen A Johnstone; Ami Mankodi; Codrin Lungu; Charles A Thornton; Douglas Esson; Adrian M Timmers; William W Hauswirth; Maurice S Swanson
Journal:  Science       Date:  2003-12-12       Impact factor: 47.728

9.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.

Authors:  Ami Mankodi; Masanori P Takahashi; Hong Jiang; Carol L Beck; William J Bowers; Richard T Moxley; Stephen C Cannon; Charles A Thornton
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.

Authors:  Nicolas Charlet-B; Rajesh S Savkur; Gopal Singh; Anne V Philips; Elizabeth A Grice; Thomas A Cooper
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

View more
  42 in total

1.  Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel.

Authors:  Zhen Zhi Tang; Viktor Yarotskyy; Lan Wei; Krzysztof Sobczak; Masayuki Nakamori; Katy Eichinger; Richard T Moxley; Robert T Dirksen; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2011-12-02       Impact factor: 6.150

Review 2.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

3.  RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.

Authors:  Johanna E Lee; C Frank Bennett; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

4.  Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

Authors:  Linda L Bachinski; Keith A Baggerly; Valerie L Neubauer; Tamara J Nixon; Olayinka Raheem; Mario Sirito; Anna K Unruh; Jiexin Zhang; Lalitha Nagarajan; Lubov T Timchenko; Guillaume Bassez; Bruno Eymard; Josep Gamez; Tetsuo Ashizawa; Jerry R Mendell; Bjarne Udd; Ralf Krahe
Journal:  Neuromuscul Disord       Date:  2013-11-15       Impact factor: 4.296

5.  Alternative Splicing of Four Trafficking Genes Regulates Myofiber Structure and Skeletal Muscle Physiology.

Authors:  Jimena Giudice; James A Loehr; George G Rodney; Thomas A Cooper
Journal:  Cell Rep       Date:  2016-11-15       Impact factor: 9.423

6.  Extensive alternative splicing transitions during postnatal skeletal muscle development are required for calcium handling functions.

Authors:  Amy E Brinegar; Zheng Xia; James Anthony Loehr; Wei Li; George Gerald Rodney; Thomas A Cooper
Journal:  Elife       Date:  2017-08-11       Impact factor: 8.140

7.  Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.

Authors:  Tara E Crawford Parks; Kristen A Marcellus; Christine Péladeau; Bernard J Jasmin; Aymeric Ravel-Chapuis
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

Review 8.  The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins.

Authors:  Twishasri Dasgupta; Andrea N Ladd
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-08-17       Impact factor: 9.957

9.  Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

Review 10.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.